Resmed Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
9.1%projected annual EPS growth
Analyst Coverage
15analysts covering
FY Revenue (est.)
$5.8Bnext fiscal year
FY EPS (est.)
$12.10next fiscal year
Monitoring Framework
Key Performance Indicators
Apnea-Hypopnea Index (AHI) DailyTarget: Below 5.0 events per hour (considered normal sleep)
myAir Sleep Score DailyTarget: 70 or above (out of 100)
Non-GAAP Gross Margin Quarterly6,280.0%Target: Sustained sequential and year-over-year expansion
Watch Items
- GLP-1 Weight-Loss Drug Adoption ImpactTrigger: Significant decline in new patient CPAP setups or mask resupply ratesAction: Re-evaluate long-term sleep apnea device TAM and adjust device sales growth forecasts.
- Philips Respironics Market Re-entryTrigger: Philips resolving regulatory consent decrees and regaining material CPAP market shareAction: Assess competitive pricing pressure and potential erosion of ResMed's market share gains.
Research as of 2 Sep 2026